# Cemiplimab/Peg-Interferon-α in Advanced CSCC

> **NCT05729139** · PHASE1 · WITHDRAWN · sponsor: **Baptist Health South Florida**

## Conditions studied

- Cutaneous Squamous Cell Carcinoma
- Squamous Cell Carcinoma
- Advanced Squamous Cell Carcinoma

## Interventions

- **DRUG:** Cemiplimab-Rwlc
- **DRUG:** PEG-IFN alfa-2a

## Key facts

- **NCT ID:** NCT05729139
- **Lead sponsor:** Baptist Health South Florida
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-07
- **Primary completion:** 2026-07
- **Final completion:** 2028-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** PI is leaving institution prior to study opening for accrual.
- **Last updated:** 2023-08-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05729139

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05729139, "Cemiplimab/Peg-Interferon-α in Advanced CSCC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05729139. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*